RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.
RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.